[go: up one dir, main page]

WO1992013553A3 - Procede et agents favorisant la cicatrisation - Google Patents

Procede et agents favorisant la cicatrisation Download PDF

Info

Publication number
WO1992013553A3
WO1992013553A3 PCT/US1992/001026 US9201026W WO9213553A3 WO 1992013553 A3 WO1992013553 A3 WO 1992013553A3 US 9201026 W US9201026 W US 9201026W WO 9213553 A3 WO9213553 A3 WO 9213553A3
Authority
WO
WIPO (PCT)
Prior art keywords
wound healing
mip
agents
promoting wound
binding
Prior art date
Application number
PCT/US1992/001026
Other languages
English (en)
Other versions
WO1992013553A2 (fr
Inventor
Thomas J Fahey Iii
Barbara A Sherry
Anthony Cerami
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24615896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1992013553(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Priority to AT92907025T priority Critical patent/ATE201827T1/de
Priority to AU14284/92A priority patent/AU671073B2/en
Priority to EP92907025A priority patent/EP0579626B1/fr
Priority to JP4506649A priority patent/JPH06505983A/ja
Priority to DE69231860T priority patent/DE69231860D1/de
Publication of WO1992013553A2 publication Critical patent/WO1992013553A2/fr
Publication of WO1992013553A3 publication Critical patent/WO1992013553A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)

Abstract

La présente invention se rapporte au traitement d'un dysfonctionnement de la cicatrisation, lequel consiste à administrer un ou plusieurs modulateur(s) de cicatrisation. Le modulateur de cicatrisation peut être choisi parmi des agents de cicatrisation appropriés et leurs partenaires de liaison, en particulier des agents favorisant la cicatrisation. L'agent peut comprendre une cytokine ou un mélange de cytokines qui sont aussi susceptibles de se lier à l'héparine, et peut provoquer une inflammation localisée caractérisée par une infiltration des cellules polymorphonucléaires lorsqu'il est administré par voie sous-cutanée. Des agents particuliers se composent des cytokines inflammatoires MIP-1, MIP-1α, MIP-1β, et MIP-2. Des utilisations diagnostiques et thérapeutiques sont proposées, et des compositions pharmaceutiques sont aussi décrites.
PCT/US1992/001026 1991-02-07 1992-02-07 Procede et agents favorisant la cicatrisation WO1992013553A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AT92907025T ATE201827T1 (de) 1991-02-07 1992-02-07 Methoden und mittel zur förderung der wundheilung
AU14284/92A AU671073B2 (en) 1991-02-07 1992-02-07 Method and agents for promoting wound healing
EP92907025A EP0579626B1 (fr) 1991-02-07 1992-02-07 Procede et agents favorisant la cicatrisation
JP4506649A JPH06505983A (ja) 1991-02-07 1992-02-07 創傷治癒の促進方法および促進薬
DE69231860T DE69231860D1 (de) 1991-02-07 1992-02-07 Methoden und mittel zur förderung der wundheilung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/652,198 US5145676A (en) 1981-09-08 1991-02-07 Method and agents for promoting wound healing
US652,198 1991-02-07

Publications (2)

Publication Number Publication Date
WO1992013553A2 WO1992013553A2 (fr) 1992-08-20
WO1992013553A3 true WO1992013553A3 (fr) 1992-09-17

Family

ID=24615896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/001026 WO1992013553A2 (fr) 1991-02-07 1992-02-07 Procede et agents favorisant la cicatrisation

Country Status (8)

Country Link
US (1) US5145676A (fr)
EP (1) EP0579626B1 (fr)
JP (1) JPH06505983A (fr)
AT (1) ATE201827T1 (fr)
AU (1) AU671073B2 (fr)
CA (1) CA2103676A1 (fr)
DE (1) DE69231860D1 (fr)
WO (1) WO1992013553A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650147A (en) * 1981-09-08 1997-07-22 The Rockefeller University Methods of stimulating granulocyte-macrophage progenitor cells
US5703206A (en) * 1981-09-08 1997-12-30 Univ Rockefeller Macrophage inflammatory protein 2 (MIP-2)
US5616688A (en) * 1981-09-08 1997-04-01 The Rockefeller University Macrophage-derived inflammatory mediator (MIP-1α and MIP-1β)
US5741484A (en) * 1981-09-08 1998-04-21 The Rockefeller University Macrophage-derived inflammatory mediator (MIP-1α and MIP-1β)
EP0763543A2 (fr) * 1988-09-02 1997-03-19 The Rockefeller University Une méthode pour la préparation d'une cytokine inflammatoire (MIP-2) et des applications diagnostiques et thérapeutiques pour la cytokine ou ses anticorps
FR2648350B1 (fr) * 1989-06-20 1994-07-01 Roussel Uclaf Utilisation de lipopolysaccharides extraits de bacteries gram(-) pour la fabrication d'un medicament facilitant la cicatrisation de la peau
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
JPH0782169A (ja) * 1993-09-13 1995-03-28 Toray Ind Inc 創傷治療剤
US5602301A (en) 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
US5504003A (en) * 1994-03-08 1996-04-02 Human Genome Sciences, Inc. Macrophage inflammatory protein-3 and -4
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6488925B2 (en) 1993-12-22 2002-12-03 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6623942B2 (en) 1994-03-08 2003-09-23 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polynucleotides
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US5607388A (en) * 1994-06-16 1997-03-04 Hercules Incorporated Multi-purpose wound dressing
US5556375A (en) * 1994-06-16 1996-09-17 Hercules Incorporated Wound dressing having a fenestrated base layer
US5522794A (en) * 1994-06-16 1996-06-04 Hercules Incorporated Method of treating human wounds
US5747600A (en) * 1994-06-24 1998-05-05 Fang; Ta-Yun Reconstitutable polyacrylamide materials and methods for producing same
US7091181B2 (en) * 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US5981231A (en) 1996-06-17 1999-11-09 Human Genome Sciences, Inc. Polynucleotides encoding chemokine β-15
JPH10206424A (ja) * 1997-01-21 1998-08-07 Kitasato Inst:The 創傷進展度測定検査方法、測定用キット、及び創傷面治療法決定方法
US6670337B1 (en) 1998-01-29 2003-12-30 Yeda Reaearch And Development Co., Ltd. Facilitation of wound healing with CM101/GBS toxin
US5858991A (en) * 1997-01-29 1999-01-12 Vanderbilt University Facilitation of wound healing with CM101/GBS toxin
RU2192266C2 (ru) * 2000-12-13 2002-11-10 Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра СО РАМН Способ подготовки дефекта кожного покрова к аутодермопластике
WO2002083046A1 (fr) 2001-04-16 2002-10-24 Pamela Howard Systeme de pansement pour blessure
US7297343B2 (en) 2001-07-31 2007-11-20 Biosurface Engineering Technologies, Inc. Bioactive medical films
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
WO2006135848A2 (fr) * 2005-06-10 2006-12-21 Pamela Howard Systeme de traitement des plaies
US9095562B2 (en) * 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
CN101945994A (zh) * 2007-12-19 2011-01-12 再生科学有限责任公司 促进干细胞移植和植入的组合物和方法
EP2257176B1 (fr) 2008-03-14 2013-09-18 Regenerative Sciences, LLC Compositions et procédés pour la réparation de cartilage
WO2010065854A1 (fr) 2008-12-05 2010-06-10 Regenerative Sciences, Llc Procédés et compositions pour faciliter la réparation de tissu avasculaire
JP2013544361A (ja) * 2010-11-23 2013-12-12 ケーシーアイ ライセンシング インク バイオマーカーを用いた創傷の診断及び治療用の装置及び方法
PL2726603T3 (pl) 2011-06-29 2020-10-05 Biorestorative Therapies, Inc. Kompozycje i sposoby dotyczące brązowych komórek tłuszczowych

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0310136A2 (fr) * 1987-10-02 1989-04-05 The Rockefeller University Médiateur inflammatoire dérivé des macrophages (MIP-1 alpha et MIP-1 bêta)
WO1990002762A1 (fr) * 1988-09-02 1990-03-22 The Rockefeller University Mediateur inflammatoire derive de macrophages (mip-2)
EP0409040A1 (fr) * 1989-07-10 1991-01-23 The Rockefeller University Anticorps pour Promoteurs de l'activité du facteur de stimulation de colonies
WO1992000326A1 (fr) * 1990-06-22 1992-01-09 Chiron Corporation PROTEINE 2β INFLAMMATOIRE PRODUITE PAR LES MACROPHAGES HUMAINS
WO1992000327A1 (fr) * 1990-06-22 1992-01-09 Chiron Corporation PROTEINE 2α INFLAMMATOIRE PRODUITE PAR LES MACROPHAGES HUMAINS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0310136A2 (fr) * 1987-10-02 1989-04-05 The Rockefeller University Médiateur inflammatoire dérivé des macrophages (MIP-1 alpha et MIP-1 bêta)
WO1990002762A1 (fr) * 1988-09-02 1990-03-22 The Rockefeller University Mediateur inflammatoire derive de macrophages (mip-2)
EP0409040A1 (fr) * 1989-07-10 1991-01-23 The Rockefeller University Anticorps pour Promoteurs de l'activité du facteur de stimulation de colonies
WO1992000326A1 (fr) * 1990-06-22 1992-01-09 Chiron Corporation PROTEINE 2β INFLAMMATOIRE PRODUITE PAR LES MACROPHAGES HUMAINS
WO1992000327A1 (fr) * 1990-06-22 1992-01-09 Chiron Corporation PROTEINE 2α INFLAMMATOIRE PRODUITE PAR LES MACROPHAGES HUMAINS

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cytokine, vol. 2, no. 2, March 1990, (Philadelphia, PA, US), T.J. FAHEY III et al.: "Cytokine production in a model of wound healing: the appearance of MIP-1, MIP-2, cachetin/TNF and IL-I", pages 92-97 *
Molucular and Cellular Biology, vol. 10, no. 10, October 1990, (Washington, DC, US), N. IIDA et al.: "Cloning and sequencing of a new gro transcript from activated human monocytes: Expression in leukocytes and wound tissue", pages 5596-5599 *
Proc. Natl. Acad. Sci. USA, vol. 87, October 1990, (Washington, DC, US), S. HASKILL et al.: "Identification of three related human GRO genes encoding cytokine functions", pages 7732-7736, see especially page 7735: "Note added in proof" *
The FASEB Journal, vol. 4, no. 3, 26 February 1990, (Bethesda, MD, US), T.J. FAHEY III et al.: "Macrophage inflammatory protein 1 (MIP-1) stimulated wound fibroblast production of IL-1 and IL-6", page A624, abstract no. 2078 *

Also Published As

Publication number Publication date
JPH06505983A (ja) 1994-07-07
WO1992013553A2 (fr) 1992-08-20
US5145676A (en) 1992-09-08
CA2103676A1 (fr) 1992-08-08
AU671073B2 (en) 1996-08-15
ATE201827T1 (de) 2001-06-15
EP0579626A1 (fr) 1994-01-26
AU1428492A (en) 1992-09-07
DE69231860D1 (de) 2001-07-12
EP0579626B1 (fr) 2001-06-06

Similar Documents

Publication Publication Date Title
WO1992013553A3 (fr) Procede et agents favorisant la cicatrisation
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
AU4199489A (en) Composition for the treatment of erectile dysfunction
EP2359855A3 (fr) Procédés d'administration d'anticorps anti-TNFalpha
NO20013727L (no) Anvendelse av Botulinumtoksin B for fremstilling av et medikament
EP0335637A3 (fr) Peptides facteurs de croissance des nerfs
HUP9902429A2 (hu) TNF-receptor-asszociált faktor (TRAF) modulátorok előállítása és alkalmazása
MXPA04001942A (es) Composiciones farmaceuticas a base de timosina ??4(t??4), analogos, isorformas y otros derivados para curar o prevenir la inflamacion, el dano y otros cambios que ocurren antes, despues de, durante o inmediatamente despues de un evento micardico.
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
TR200102107T2 (tr) Tümör nekroz faktör antagonistleri ve endometriozda kullanımları.
IT8720771A0 (it) Composizioni farmaceutiche per la prevenzione e terapia della calcolosi delle vie biliari e della dispepsia biliare.
EP0570022A3 (fr) Composés chélatants qui possédant un groupe ortho-ligand et leurs complèxes
AU1843397A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
SE9603725D0 (sv) New teatment
WO2001054706A3 (fr) Methode de traitement d'affections renales
AU2002227052A1 (en) Treatments for neurogenetic disorders, impulse control disorders, and wound healing
WO1999059617A3 (fr) Immunoregulateur
CA2156481A1 (fr) Compositions antagonistes du recepteur 5-ht2, utiles pour le traitement des troubles veineux
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
WO1999055861A3 (fr) Compositions de muteine du facteur de croissance de fibroblastes et procedes d'utilisation associes
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
KR910700051A (ko) S-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암 조성물 및 암의 치료방법
WO1998020835A3 (fr) Methode pour traiter l'hyperlipidemie chez l'homme
WO1997007136B1 (fr) Composition pharmaceutique contenant des inhibiteurs de l'inteferon gamma
ITRM920305A1 (it) Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

WWE Wipo information: entry into national phase

Ref document number: 2103676

Country of ref document: CA

Ref document number: 1992907025

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992907025

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1992907025

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992907025

Country of ref document: EP